Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Brain and Behaviour > Neurotransmission and Neuromodulation > Flashcards

Neurotransmission and Neuromodulation Flashcards

You may prefer our related Brainscape-certified flashcards:
The Brain flashcards
1
Q

Structure of a neuron

A

· Dendrites - recipient of information from other neurons, large receptive field
· Soma (cell body) - contains the machinery that controls processing in the cell and integrates information
· Axon - carries information (action potential) from the soma to the terminal boutons and hence to other cells. Axons can branch to contact multiple neurons
- Terminal Boutons - found at the end of the axon, location of the synapse, communication point with other neuron

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

neuronal membrane

A

· Boundary of soma, dendrites, axon and terminal boutons.
· Separates the extracellular environment from the intracellular environment
· Membrane - lipid bilaver (5nm)
· Protein structures:
- Detect substances outside of the cell
- Allow access of certain substances into the cell (gated - chemical or electrical) cytoskeletal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

the synapse

A

· Types of synapse:
1. Electrical synapse:
- very rare in adult mammalian neurons (e.g., found in retina)
- Junction between the neurons is very small (3nm - gap junction)
- Gap is spanned by proteins (connexins) which are used to communicate between the neurons (ions move freely)
2. Chemical synapses:
- Common in adult mammalian neurons
- Junction between the neurons 20-50nm (synaptic cleft)
- Chemicals (neurotransmitters) are released from the presynaptic neuron to communicate with the postsynaptic neurons.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Early experimental evidence for chemical transmission:

A

· First demonstrated by Loewi in the 1920s
· Application of fluid following vagus nerve stimulation slowed down heart rate
· Substance was ‘sufficient’ to change heart activity
- Acceptance as primary means of communication in the brain in ’60s

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Overview of chemical transmission:

A
  1. Neurotransmitter (NT) synthesis, transport and storage
    1. Depolarisation (action potential)
    2. Open voltage-gated Ca2+ channel
    3. Ca2+ influx
    4. Movement and docking of vesicles
    5. Exocytosis-diffusion
    6. And 8 interact with receptors
      · In/deactivation of NTs
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Neurotransmitters:

A

· Chemical that is used to transmit information from the presynaptic neuron to the postsynaptic neuron
· Criteria for neurotransmitter:
1. Chemical synthesised presynaptically
2. Electrical stimulation leads to the release of the chemical
3. Chemical produces physiological effect
4. Terminate activity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Postsynaptic action of the neurotransmitter:

A
  • Neurotransmitter binds to receptors on the postsynaptic membrane, which affects the activity of the postsynaptic cell.
    • The configuration of the receptors make them specific for different neurotransmitters.
    • Ionotropic receptor - opening of an ionic channel (typically)
    • Metabotropic receptor - activates an internal 2nd messenger systems that goes on to affect the functioning of the postsynaptic cells.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Action of neurotransmitters at receptors:

A
  • Pharmacology - what transmitter binds to the receptor and how drugs interact
    • Receptors vary in their pharmacology:
    • Agonist - a drug (or endogenous ligand/neurotransmitter) that can combine with a receptor on a cell to produce a cellular reaction.
    • Antagonist - a drug that reduces or completely blocks the activity of the agonist or endogenous ligand, no cellular effect after interacting with receptor.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Actions of neurotransmitters at receptors 2:

A

· Receptors vary in their:
- Kinetics - rate of transmitter binding and channel gating determine the duration of effects
- Selectivity - what ions are fluxed (Na+, Cl-, K+ and/or Ca2+)
- Conductance - the rate of flux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Ionotropic receptors:

A

· Fast transmission - ion movement leads to an immediate change in the postsynaptic cell
· Excitatory fast transmission:
- Ion channels opens
- Movement of positive ions into the neurone (Na+)
- E.g., glutamate receptors
- Depolarisation
- Excitatory post synaptic potential (EPSP)
· Inhibitory fast transmission:
- Ion channels opens
- Movement of negative ions into the neurone (Cl-)
- E.g., GABAa receptors
- Hyperpolarisation
- Inhibitory post synaptic potential (IPSP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Metabotropic receptor:

A

· Activation of a G-protein coupled receptor:
1. Neurotransmitter binds to receptor and activates the G-protein (exchange GDP for GTP)
2. G protein splits and activates other enzymes
3. The breakdown of GTP turns off G protein activity
4. Series of chemical reactions that leads to an amplification of the signal - second messenger system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Amplification:

A
  • Example of amplification of signal through G-protein coupled receptor activation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Neurotransmitter deactivation:

A
  • Neurotransmitters must be inactivated after use to remove them from the synaptic cleft.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Other ways of regulating synaptic transmission - autoreceptors:

A
  • Located on the presynaptic terminal
    • Respond to neurotransmitter in the synaptic cleft
    • Generally they are G-protein coupled - don’t directly open ion channels
    • Regulate internal process controlling the synthesis and release of neurotransmitter
    • Negative feedback mechanism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Neurotransmitters :

A
  • Major classes
    • Integration of excitatory and inhibitory signals
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Fast synaptic transmission:

A
  • Glutamate - ionotropic receptors in general flux Na+ which causes an EPSP (excitatory post synaptic potential) depolarising the postsynaptic neuron - excitatory
    • GABA - ionotropic receptors flux Cl-, which causes as IPSP (inhibitory post synaptic potential) hyperpolarising the postsynaptic neuron - inhibitory
    • Acetylcholine, serotonin and ATP also activate ionotropic receptors
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Glutamate:

A
  • Major fast excitatory neurotransmitter in the CNS
    • Very widespread through the CNS
    • Activates different types of receptors - mGluR, NMDA, AMPA, Kainate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Glutamate synthesis, storage, release and reuptake:

A
  1. Synthesised in nerve terminals from glucose or glutamine
    1. Loaded and stored in vesicles by vesicular glutamate transporters
    2. Released by exocytosis (Ca2+ dependent mechanism)
    3. Acts at glutamate receptors on postsynaptic membrane
    4. Reuptake by excitatory amino acid transporters (EAATs) in the plasma membrane of presynaptic cell and surrounding glia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Glutamate receptor diversity:

A
  • Based on their pharmacology, three types of ionotropic receptor have been described that respond to glutamate - NMDA, AMPA, and Kainate
    • They are named based on the agonists selective for them
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

AMPA receptor:

A
  • Ionotropic receptor
    • Binding of glutamate leads to the opening of a Na+ channel (slight K+ permeability) and hence depolarisation
    • Selective agonists - AMPA
    • Antagonists - CNQX, DNQX
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

NMDA receptor:

A
  • Ionotropic receptor
    • Permeable to Na+, K+ and Ca2+
    • Binding of glutamate - nothing happens
    • Voltage dependent blockade:
    • At resting membrane potential (-65mV):
    • Glutamate binds
    • Channel opens
    • Blocked by Mg2+
    • Depolarised membrane (-30mV):
    • Mg2+ pushed out of pore
    • Channel is open
    • Ion movement
    • Further depolarisation
      · Different ‘kinetics’ from AMPA receptor (open much longer)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Selectivity and conductance of glutamate receptors:

A

· AMPA (and kainate) receptors:
- Fast opening channels permeable to Na+ and K+
· NMDA receptors:
1. Slow opening channels - permeable to Ca2+ as well as Na+ and K+
· BUT also
2. Requires glycine as a cofactor (no glycine, no activation)
3. And gated by membrane voltage
· NMDA receptors are only activated in an already depolarised membrane in the presence of glutamate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

NMDA receptors - dysregulation:

A

· NMDA receptors and schizophrenia?:
- NMDA receptors also blocked by phencyclidine (PCP, angel dust) and MK801 which both bind in the open pore
- Blockade of NMDA receptors in this way produces symptoms that resemble the hallucinations associated with schizophrenia (associated with reduced NMDAR function)
- Certain antipsychotic drugs enhance current flow through NMDA channels
· Glutamate excitotoxicity:
- Caused by excessive Ca2+ influx into the cell which activates calcium dependent proteases and phospholipases that damage the cell
- This kind of cell damage occurs after stroke and chronic stress

24
Q

GABA:

A

· GABA (gamma aminobutyric acid)
· Major inhibitory neurotransmitter
· Activates an ionotropic receptor (GABAa receptor) which opens a chloride channel (Cl-) leading to hyperpolarisation (IPSP)

25
Q

GABA synthesis, storage, release and reuptake:

A
  1. GABA is synthesized from glutamate
    1. GABA is loaded and stored into synapses by a vesicular GABA transporter
    2. GABA released by exocytosis (Ca2+ dependent mechanism)
    3. GABA acts at ionotropic GABAA and metabotropic GABAB receptors on postsynaptic membrane
    4. GABA cleared from synapse by reuptake using transporters on glia and neurons including non-GABAergic neurons
26
Q

GABA receptor diversity:

A
  • Two main families of GABA receptor:
    • GABAa ionotropic receptors:
    • Ligand gated Cl- channel
    • Fast IPSPs
    • GABAb metabotropic receptors:
    • G protein coupled receptors
    • Indirectly coupled to K+ or Ca2+ channel through 2nd messengers
    • Opens K+ channel, closes Ca2+ channel
    • Slow IPSPs
27
Q

Regulation of amino acid transmitter release:

A

· Too much glutamate / too little GABA
- hyperexcitability – epilepsy
- excitotoxicity
· Too much GABA
- sedation/coma
- (At right dose, drugs which increase GABA transmission can be used to treat epilepsy)
· Cerebral ischemia
- the metabolic events that retain the electrochemical gradient are abolished
- reversal of the Na+ K+ gradient
- transporters release glutamate from cells by reverse operation
- excitotoxic cell death.
· GHB gamma-hydroxybutyrate (date rape drug)
- a GABA metabolite that can be converted back to GABA by transamination
- Increases amount of available GABA
- Moderate dose like alcohol, but too much leads to unconsciousness and coma

28
Q

Unconsciousness, coma, and death also from excessive alcohol:

A

· Quite drunk - BAC of 0.2 - 0.3
· Death - BAC of 0.35 - 0.5
· But typically one passes out before ingesting lethal dose

29
Q

GABAa receptors and drugs:

A

· Complex receptor with multiple binding sites
· Drugs binding at GABA binding site
· Muscimol – agonist
· Bicuculine, picrotoxin – antagonist
· “They eat certain fungi in the shape of fly-agarics, and thus they become drunk worse than on vodka, and for them that’s the very best banquet.” -
· Drugs binding elsewhere on the receptor (no competition with GABA)
- Benzodiazepine
- Barbiturates
- Ethanol
- Neurosteroids
· net result more inhibitory Cl- current, stronger IPSPs and behavioural consequences of enhanced inhibition

30
Q

Drugs increasing GABA activity reduce anxiety (anxiolytic):

A

· Agonists - alcohol, barbiturates
· Indirect agonist - benzodiazepines (BDZ)

31
Q

Drugs decreasing GABA activity increase anxiety (anxiogenic):

A

· Antagonist - flumazenil
· These drugs all act at the GABAa ionotropic receptor

32
Q

Barbiturates:

A

· Problems:
a. General (non-specific) depression of neuronal activity - includes vital functions like breathing
b. Poor therapeutic ratio. Small difference between therapeutic dose and overdose. High suicide risk in emotionally unstable patients.
c. Long-term treatment leads to dependence and withdrawal
d. Thus, only used for severe insomnia, seizures.

33
Q

Benzodiazepines:

A
  • Discovered in 1960s
    • First benzodiazepine was chlordiazepoxide (Librium)
    • Shortly after that diazepam (Valium) became the major treatment for anxiety disorders
    • Act as:
    • Anxiolytic
    • Anticonvulsant
    • sedative
    • Muscle relaxant
    • amnestic
    • Advantages:
    • Good, fast acting anxiolytics
    • Large therapeutic window
    • Disadvantages:
    • May cause dependence
    • Effects potentiated by alcohol
34
Q

Other classical neurotransmitter:

A

· Dopamine
· Serotonin
· Acetylcholine

35
Q

Neurotransmission vs neuromodulation (rule of thumb):

A

· Primary neurotransmitters
- Glutamate and GABA - the main workhorses of the brain
- Directly mediate the transmission of information between neurons either via activation (excitation, EPSPs) or inactivation (inhibition, IPSPs) of post-synaptic targets
· Some neurotransmitters are ‘Neuromodulators’
- Affect the response properties of a neuron (e.g. release, excitability) - do not carry primary information themselves.
- e.g. dopamine, serotonin, noradrenaline, acetylcholine (others: histamine, neuropeptides)

36
Q

The diffuse modulatory systems:

A

· Specific populations of neurons that project diffusely and modulate the activity of glutamate and GABA neurons in their target areas

37
Q

The dopaminergic system:

A

· Dopamine neurons
- cell bodies in the midbrain
- project into the forebrain
· Nigrostriatal system (substantia nigra projections to neostriatum (caudate and putamen) role in movement.
- dysfunction:
- Parkinson’s disease - destruction of DA projections from SN to basal ganglia
- Huntington’s disease - destruction of DA target neurons in striatum
· Mesolimbic system (ventral tegmental area projections to nucleus accumbens (NAcc) role in reinforcement (reward)
- dysfunction:
- Addiction - most drugs of abuse lead to enhanced DA release in the NAcc
· Mesocortical system (VTA projections to prefrontal cortex) role in functions such as working memory and planning.
- dysfunction: Schizophrenia

38
Q

1 - dopamine synthesis:

A

· Tyrosine - essential amino acid obtained in diet
- Catalysed by tyronsine hydroxylase (TH)
- Rate limiting step (or slowest step)
· L-dopa
- Catalysed by dopa decarboxylase
· Dopamine

39
Q

2 - Catecholamine storage:

A

· Loaded into vesicles

40
Q

Drugs that affect dopamine synthesis and storage modulate behaviour:

A

· Reserpine impairs storage of monoamines in synaptic vesicles. (The vesicles remain empty resulting in no transmitter release upon activation)
· L-DOPA, the precursor of dopamine, is used as a treatment for Parkinson’s disease. (Bypasses rate-limiting TH step – Dopa decarboxylase converts it into dopamine increases the pool of releasable transmitter)
· AMPT (a-methyl-p-tyrosine) inactivates TH (used experimentally – not in treatment)
· Role and importance of neurotransmitter systems in behaviour revealed by drugs (e.g. Reserpine was used to treat high blood pressure but caused depression)

41
Q

3 - dopamine release:

A

· depolarization of presynaptic membrane
· influx of Ca2+ through voltage gated Ca2+ channels
· Ca2+ dependent vesicle docking and Release (Ca2+ dependent exocytosis)

42
Q

5 - Dopamine reuptake / metabolism

A

· Signal terminated by reuptake into the axon terminal by transporters powered by electrochemical gradient (Dopamine transporters (DATs))
· in the cytoplasm dopamine is:
- reloaded back into vesicles
- enzymatically degraded by Monoamine oxidases (MAOs) or Catechol-O-methyl-transferase (COMT)

43
Q

Drugs that affect dopamine release and reuptake modulate behaviour:

A

· Cocaine, Amphetamine and Methylphenidate (Ritalin) - psychostimulants
- all block the reuptake of monoamines into terminals. More dopamine in synaptic cleft
- extended action of dopamine on postsynaptic neuron.
- (Amphetamine reverses transporter so pumps out transmitter - uncontrolled release)
· Selegiline – Monoamine oxidase B inhibitor
· Entacapone - COMT inhibitor
- prevent the breakdown of catecholamines,
- increases the releasable pool
· These drugs can have antidepressant activity and can be used for treating Parkinson’s

44
Q

The serotonergic system:

A

· Nine raphe nuclei (in brain stem) with diffuse projections
- each projects to a different part of the brain
· Descending projections to cerebellum and spinal cord (pain)
· Ascending projections (reticular activating system (with Locus Coeruleus))
· Dorsal and medial raphe project throughout the cerebral cortex
· raphe neurons:
- fire tonically during wakefulness
- quiet during sleep
· Function in:
- mood
- sleep
- pain
- emotion
- appetite

45
Q

1 - serotonin synthesis:

A

· Tryptophan - essential amino acid
- Rate limiting
- E.g., tryptophan, hydroxylase
· 5-hydroxytryptophan (5-HTP)
- E.g., aromatic amino acid, decarboxylase
· Serotonin (5-hydroxytryptamine, 5-HT)
· Tryptophan and mood:
- Depletion diet - method of experimentally inducing a depressive state
- Enrichment - improving mood

46
Q

2 - Serotonin storage:

A

· Loaded into vesicles

47
Q

3 - Serotonin release:

A

· Ca2+ dependent exocytosis

48
Q

5 - Serotonin reuptake / metabolism:

A

· signal terminated by reuptake by Serotonin transporters (SERTs) on presynaptic membrane
· degraded by MAOs in the cytoplasm

49
Q

Drugs that affect serotonin release and reuptake modulate behaviour:

A

· Fluoxetine (Prozac) blocks reuptake of serotonin (SSRI – selective serotonin reuptake inhibitor) – antidepressant / anti-anxiety
· Fenfluramine causes the release of serotonin and inhibits its reuptake (has been used as an appetite suppressant in the treatment of obesity)
· MDMA 3,4-methylenedioxy-methamphetamine (ecstasy) causes noradrenaline and serotonin transporters (SERT) to work in reverse releasing neurotransmitter into synapse/extracellular space
· Monoamine oxidase inhibitors (boost monoamines)

50
Q

The cholinergic system:

A

· In the periphery
- Acetylcholine (ACh) at neuromuscular junction (NMJ) and synapses in the autonomic ganglia
· In the brain:
- Basal forebrain complex
- Projections to hippocampus and cortex
· Pontomesencephalotegmental complex
- cholinergic link between the brain stem and basal forebrain complex

51
Q

Cholinergic interneurons in the striatum and the cortex:

A

· Each interneuron innervates 1000’s of logical principal neurons and modulates their activity

52
Q

Acetylcholine:

A
  1. Synthesis:
    · made from choline amount of choline is rate limiting step
    1. Storage:
      * loaded into vesicles
    2. Release:
      * Ca2+ dependent exocytosis
    3. 5 - Metabolism:
      * rapidly degraded in synaptic cleft by acetylcholinesterase
      * Choline is transported back into the presynaptic terminal and converted to acetylcholine
      * (acetylcholinesterase is made by the cholinergic neuron, secreted into synaptic cleft and associated with the axonal membrane)
53
Q

Drugs affecting acetylcholine release, storage and degradation modulate behaviour (or neurological function):

A

· Acetylcholinesterase inhibitors
- block the breakdown of ACh thus prolonging its actions in the synaptic cleft
· e.g. Physostigmine
· treatments for Alzheimer’s disease, Myasthenia gravis (autoimmune disorder, AchR’s destroyed)

54
Q

Drugs affecting vesicle docking and release:

A

· ACh release at neuro-muscular junction, NMJ
· Botulinum and tetanus toxins
- (from bacteria Clostridium botulinum and tetani respectively)
- blocks the docking of vesicles by attacking SNAREs- no release
· Botox acts directly at synapse in NMJ
- The muscles lose all input and so become permanently relaxed.

55
Q

Drugs affecting vesicle docking and release

A

· (ACh release at Neuro-Muscular Junction, NMJ)
· Tetanus toxin is retrogradely transported up at NMJ and works at inhibitory (Glycine) synapses on cholinergic motor neurons of spinal cord
- Also attacks SNARE proteins
- (Inhibiting the release of Glycine at these sites “disinhibits” the cholinergic neurons so they continuously fire resulting in permanent muscle contraction, ‘lock jaw’)

56
Q

Disorders of the cholinergic system:

A

· Peripheral
- Myasthenia gravis - Autoimmune disease - destroys cholinergic receptors in the muscle - muscle weakness and eventual loss of muscle activity
· Brain
- Alzheimer’s disease
- Loss of cholinergic neurons in the basal ganglia - possibly underlies deficits in memory associated with the disease.
- →Drugs that increase acetylcholine help (e.g. donepezil)
· Addiction
- nicotine addiction
· Other psychiatric disorders
- Schizophrenia (Comorbidity with smoking)

Brain and Behaviour (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions